ProstaLund

Fourth quarter

October 1 - December 31

• Net sales amounted to SEK 3,9 million (6,4)
• Operating result amounted to SEK -6,2 million (-3,5)
• Profit after tax amounted to SEK -6,2 million (-3,5)
• Earnings per share before and after dilution amounted to SEK -2,43 (-1,82)
• Cash flow from operating activities amounted to SEK -6,5 million (-5,6)

January 1 - December 31

• Net sales amounted to SEK 13,7 million (22,1)
• Operating result amounted to SEK -22,5 million (-16,9)
• Profit after tax amounted to SEK -22,6 million (-17,0)
• Earnings per share before and after dilution amounted to SEK -6,94 (-9,94)
• Cash flow from operating activities amounted to SEK -22,6 million (-23,7)
• Cash and cash equivalents amounted to SEK 7,8 million (15,0)

Significant events during the quarter

• First published report of transurethral intraprostatic anaesthesia (TUIA) using the Schelin Catheter® in patients undergoing holmium laser enucleation of the prostate.
• Short-term results and long-term durability after CoreTherm® treatments presented at the Emirates International Urological Conference in Dubai, UAE.
• Notice of Extraordinary General Meeting regarding a resolution on reverse share split.
• The first ten CoreTherm® Eagle machines have been manufactured.
• ProstaLund announces outcome of warrants series TO 3, with a subscription rate of 94,4%, the company received approximately SEK 3,7 million before issue costs.
• Further study published confirming the good effect of transurethral intraprostatic anaesthesia (TUIA) via our Schelin Catheter® in the treatment of benign prostatic hyperplasia.
• Nomination Committee appointed in ProstLund AB (publ) for the Annual General Meeting 2025.
• Determination of record date for reverse share split in ProstaLund AB.

Significant events after the quarter

• Older men treated with CoreTherm® for benign prostate enlargement have a lower risk of a prostate cancer diagnosis later in life compared to men treated with TURP according to a new Swedish registry study.
• New study confirms the strong efficacy of CoreTherm® in patients with large prostates.

Key figures